

Index

- abbreviations 209–10
- ABCD(E) rule 27
- abdomino-perineal resection (APR) 132, 134
- accuracy of detection 6–7
- acral lentiginous melanoma (ALM) 28, 46, 74, 75, 203
- acral lentiginous melanoma *in situ* 46, 203
- actinic keratosis 210
- acupuncture 163
- adjuvant radiation therapy 87, 88, 137
- adjuvant systematic therapy 93–4
 - evidence summary 93
 - recommendations xxx, 94
- adjuvant therapy 147, 210
- aetiology 210
- age
 - and anorectal melanoma (ARM) 131
 - and congenital melanocytic naevi patients 9
 - and desmoplastic melanoma 129
 - incidence rates xiii–xiv
 - and prognosis 158
 - risk factors 15, 145, 153
 - and sun exposure 1, 2
 - and superficial spreading melanoma (SSM) 27
- allied health professional (AHP) 210
- amelanotic melanoma 76
- American Joint Commission on Cancer (AJCC)
 - Melanoma Stageing Committee 23–6
- amputation 75, 88
- anaesthetic 210
- animal type melanoma 46, 203
- anorectal melanoma (ARM) 131
 - evidence summary 133
 - management of 132–4
 - recommendations xxxiii, 133
 - survival 133
- associated benign melanocytic lesions 43
- atypical naevi 210
- Australia
 - incidence rates xiii–xiv
 - medico-legal considerations 180–1
 - mortality rates xv–xvi
- Australian Cancer Network 183
- automated diagnostic instruments 30
- autosomal 210
- basal cell carcinoma 211
- benign 211
- biopsy 211
 - broad superficial shave 36
 - versus complete excision 38
 - complete excisional 35
 - deep shave 36, 38
 - evidence summary 37–8
 - fine needle 82
 - good practice points xxiii, 38
 - incisional 36
 - partial 35–6, 38
 - and pregnancy 151
 - punch 35, 38
 - recommendations xxiii, 38
 - sentinel lymph node 79–82
- body site of occurrence 157–8
- brachytherapy 211
- Breslow thickness 35, 41, 47, 211
 - and metastasis to lymph nodes 79
 - and prognosis 157–8
- cancer 211
- cancer care services
 - access to 174, 175
 - for Māori 175
 - for Pacific peoples 176
- Cancer Council Australia 2, 5
- Cancer Society of New Zealand 2, 5
- carcinoma 211
- CDKN2A mutations 19–20
- cell type 43, 45
- cells 211
- chemoprophylaxis 211
- chemotherapy 96, 211
- childhood melanoma 145
 - diagnosis 145–6
 - evidence summary 146, 147
 - recommendations xxxiv, 146, 147
 - survival 146–7
 - treatment 146–7

- children
 - and melanoma 145–7
 - and palliative care 205
 - see also congenital melanocytic naevi patients
- Clark's level of invasion 43
 - and prognosis 157–8
- classification and staging 23–6
 - recommendations xxii, 24
- clinical diagnosis 27–31
 - accuracy of 196–202
 - aids 29–30
 - childhood melanoma 145–6
 - evidence summary 31
 - good practice points xxii, 29
 - recommendations xxii, 31
- clinical oncologist 211
- clinical oncology 211
- clinical practice guidelines, developing 182–9
- clinical practice recommendations xix–xxxvi
- clinical trials 93, 127–8
 - evidence summary 128
 - good practice points xxxiii, 128
 - recommendations xxxiii, 128
- clinicopathological correlation 44
- cognitive behavioural therapy (CBT) 102
- cohort studies 211
- communication
 - evidence summary 106
 - with patients 105–6
 - recommendations xxxi, 106
- complementary and alternative medicine (CAM) 163–4
 - and conventional therapies 165–6
 - evidence summary 165, 166
 - recommendations xxxv, 165, 166, 167
 - value for money 166–7
 - what patients find worthwhile 164–5
- computed tomography (CT) 211
- congenital melanocytic naevi 63
- congenital melanocytic naevi patients
 - evidence summary 64, 65
 - good practice points xxv, 66
 - management of 64–6
 - recommendations xxv, 65
 - risk factors 63–4
- conjunctival melanoma 143
- consultation submissions received 194–5
- contraceptive pill 153
- cost-effectiveness
 - complementary and alternative medicine (CAM) 166–7
 - skin screening, whole-body 8–9
- curettage 36
- cytological analysis 37
- cytopathologist 211
- cytotoxic 211
- dacarbazine 95
- deep shave biopsy 33, 38
- dermatologist 211
- dermatology 211
- dermatopathologist 212
- dermatopathology 212
- dermis 212
- dermoscope 212
- dermoscopy 29–30, 212
 - versus naked eye 196–202
- descriptive reports 47
- desmoplasia 43
- desmoplastic melanoma 28, 43, 46, 203
 - evidence summary 129
 - recommendations xxxiii, 129
 - treatment of 129
- desmoplastic neurotropic melanoma 43, 129
- detection of melanoma
 - ABCD(E) rule 27
 - by doctors 27
 - by patients 27
 - rates of 6–7
- diagnosis
 - accuracy of 196–202
 - aids 29–30
 - childhood melanoma 145–6
 - clinical 27–31
- diagnostic radiographer 212
- diathermy treatment 212
- diet therapy 166
- disseminated melanoma 83, 95–7, 135
 - chemotherapy 96
 - evidence summary 97
 - recommendations xxxi, 97
 - surgical treatment 96
- dissemination of guidelines 188
- distant metastases 23, 24, 25, 58, 80, 88, 123
 - and mucosal melanoma 131, 133, 135, 136, 137

- prognosis 157–8
- drug therapy 127–8
- ear, nose and throat (ENT) 212
- educational interventions 103–4
- epidermal collarette 45
- epidermal component 45
- epidermiology 212
- epidermotropic metastasis 39
- ethnic origin 169–70
- evidence levels xx, 186
- evidence summary
 - adjuvant systematic therapy 94
 - anorectal melanoma (ARM) 133
 - biopsy 37–8
 - childhood melanoma 146, 147
 - clinical diagnosis 31
 - clinical trials 128
 - communication 106
 - complementary and alternative medicine (CAM) 165, 166
 - congenital melanocytic naevi patients 64, 65
 - desmoplastic melanoma 129
 - disseminated melanoma 97
 - follow-up 122, 123, 124
 - histopathological reporting 49, 51
 - lentigo maligna (LM) 70
 - local metastasis 88, 89
 - locoregional cutaneous melanoma 58
 - locoregional recurrent melanoma 87, 88, 89, 90
 - metastatic melanoma 60
 - mucosal melanoma 133, 135
 - multidisciplinary care 119
 - occult melanoma 141
 - ocular melanoma 143
 - palliative care 114
 - persistent melanoma 87
 - pregnancy 151, 152
 - prevention 3
 - primary melanoma 56, 74
 - psychosocial factors 108
 - psychosocial interventions 105, 109
 - regional lymph nodes 84, 90
 - risk factors 18, 20
 - sentinel lymph node biopsy (SLNB) 82
 - skin screening, whole-body 6, 7, 8, 9
 - staging 24
 - vulval melanoma 137
- excision 212
 - assessment of completeness 42
 - mapped serial 42
 - margins of 42, 73–4
 - versus partial biopsy 38–9
 - wide local 38, 73–4, 79, 80, 132, 134, 137
- executive summary xi–xii
- extravascular migratory metastasis 42
- eye-conserving therapies 143
- families, and specialist palliative care 115–16
- family history 17
- fibrosis 42, 45
- fine needle aspiration cytology (FNA) 212
- fine needle biopsy 79
- follow-up 121
 - evidence summary 122, 123, 124
 - intervals and tests 122–3
 - recommendations xxxii, 122, 124
 - undertaking 121–2
 - value of 123–4
- frozen section 37, 50
- gender 15
 - incidence rates xiii–xiv
 - mortality rates xv–xvi
 - and prognosis 158
 - risk factors 15
 - and thickness of melanoma 7–8
- gene mutations 19
- general practitioners
 - detection of melanoma 27
- good practice points
 - biopsy xxiii, 38
 - clinical diagnosis xxii, 29
 - clinical trials xxxiii, 128
 - congenital melanocytic naevi patients xxv, 66
 - high-risk individuals xxi
 - Māori xxxvi, 174
 - mucosal melanoma xxxiv, 138
 - non-Caucasians xxxvi, 171
 - Pacific peoples in New Zealand xxxvi, 176
 - primary melanoma xxvii–xxviii, 75–6
 - regional lymph nodes xxix, 84

- risk factors 18
 - histopathological reporting 41–52
- genetics 19–20
- glossary 210–16
- good practice points
 - biopsy xxiii, 38
 - clinical diagnosis xxii, 29
 - clinical trials xxxiii, 128
 - congenital melanocytic naevi patients xxv, 66
 - high-risk individuals xxi, 18
 - Māori xxxvi, 174
 - mucosal melanoma xxxiv, 138
 - non-Caucasians xxxvi, 171
 - Pacific peoples in New Zealand xxxvi, 176
 - primary melanoma xxvii–xxviii, 75–6
 - regional lymph nodes xxix, 84
- growth
 - dermal growth pattern 45
 - histological growth pattern 43
 - phase 43
- guidelines development process 182–9
 - development of method handbook 183
 - dissemination and implementation 188
 - public consultation 187–8
 - review of chapters 187
 - steps in preparing 183–9
 - writing chapters 187
- hapū 212
- head and neck
 - desmoplastic melanoma 129
 - lentigo maligna (LM) 69–71
 - mucosal melanoma 134–5
- Health Sponsorship Council of New Zealand 2
- high-risk patients
 - adjuvant systematic therapy 93
 - follow-up 123
 - good practice points xxi, 18
 - management of 18
 - risk factors 15–17
- histological growth pattern 43
- histology 212
- histopathological reporting 41
 - comments on 42–4
 - component of 41
 - evidence summary 49, 51
 - examples 48
 - format of report 47
 - lymph node dissection 51–2
 - non-sentinel lymph nodes 50–1
 - recommendations xxiii–xxiv, 49–50, 51
 - request forms 44
 - sentinel lymph nodes 50–1
 - terminology 46
- histopathologist 212
- histopathology 212
- hormone replacement therapy 153
- Hutchinson's melanotic freckle 46, 203
 - see also lentigo maligna (LM)
- immunohistochemistry 43–4
- implementation of guidelines 188
- in situ* 212
- in situ* melanoma 7, 25, 39, 42, 46, 70, 73, 203
 - follow-up 122
- in-transit metastasis 25, 42, 49, 88–90
- incidence rates xiii–xiv
 - in Indigenous communities 170
 - Māori 173
 - in non-Caucasians 169
 - Pacific peoples in New Zealand 175
- Indigenous communities 170
- inflammation 45
- interferon 93–4, 95, 165–6
 - and children 147
- invasion, level of 42
- invasive melanoma 7, 42, 46, 70, 74, 76, 79, 203
 - follow-up 122
- investigations following diagnosis
 - locoregional cutaneous melanoma 58–8
 - metastatic melanoma 59–60
 - primary melanoma 55–6
- isolated limb infusion 88–9, 212
- isolated limb perfusion 88–9, 213
- iwi 212
- kaitiaki 213
- kaupapa Māori 213
- laser therapy 213
- lentigo maligna (LM) 28, 46, 69–71, 203, 213

- evidence summary 70
- and mapped serial excision 42
- recommendations xxvi, 71
- lentigo maligna melanoma (LMM) 28, 46, 203
 - and mapped serial excision 42
- lesion thickness *see* Breslow thickness
- lesions 213
 - associated benign melanocytic 43
- linea nigra 151
- local metastasis 42, 88–90, 213
 - evidence summary 88, 89
 - histological features 45
 - recommendations 88, 89, 90
- local recurrence 213
- locoregional cutaneous melanoma
 - evidence summary 58
 - investigations following diagnosis 57–8
 - recommendations xxiv, 58
- locoregionally recurrent melanoma 87–91
 - evidence summary 87, 88, 89, 90
 - recommendations xxix–xxx, 87, 88, 89, 90, 91
- lymph nodes
 - dissection 51–2
 - regional 79–84
 - sentinel lymph node biopsy (SLNB) 79–81, 146–7, 216
- lymphadenectomy 133
- lymphadenopathy 213
- lymphovascular invasion
 - and prognosis 157–8
- macroscopic descriptions 41
- magnetic resonance imaging (MRI) 213
- male genito-urinary tract, mucosal melanoma 135–6
- malignant 213
- malignant blue naevus 46, 203
- mana 213
- management
 - of anorectal melanoma (ARM) 132–4
 - of congenital melanocytic naevi patients 64–6
 - of high-risk patients 18
 - regional lymph nodes 79–84
- Māori 173–4
 - good practice points xxxvi, 174
 - guiding principles 173
 - health perspectives 173
 - incidence rates 173
- margin 213
- maxillofacial 213
- medical oncology 213
- medico-legal considerations
 - Australia 180–1
 - New Zealand 181
- melanocyte stimulating hormone 213
- melanocytic naevi 16
- melanoma 213
 - in children 145–7
 - and congenital melanocytic naevi patients 46, 203
 - and pregnancy 152
 - previous, risk factors 16
 - terminology and synonyms 46, 203
 - thickness detected 7–8
 - unclassified 46, 203
 - uncommon variants 46, 203
- melphalan 88–9
- menstruation 153
- meta-analysis 213
- metachronous 213
- metastases 214
- metastatic melanoma
 - evidence summary 60
 - investigations following diagnosis 59–60
 - and lymph nodes 79
 - versus primary melanoma 44
 - and prognosis 157–8
 - recommendations xxiv, 60
- microsatellites 42, 49
- minimum dataset 214
- microscopic descriptions 41
- mitotic rate 42, 45
 - and prognosis 158
- mohs surgery 214
- morbidity 8, 214
- mortality xvi, 214
 - rates xv–xvi, 9
- mucosal melanoma 131
 - anorectal region 131–4
 - evidence summary 133, 135
 - good practice points xxxiv, 138
 - head and neck 134–5
 - male genito-urinary tract 135–6
 - oesophagus 135
 - and radiotherapy 133, 135

- recommendations xxxiii–xxxiv, 133, 135
 - survival 133, 135
 - vagina 137
 - vulval 136–7
- multidisciplinary care 119
 - evidence summary 119
 - and lymph node metastases 82, 84
 - and palliative care 113
 - recommendations xxxii, 119
- naevi
 - associated 45
 - and pregnancy 151
- nasal melanoma 134
- neoplasm 214
- neurotropism 43, 49, 129
- New Zealand
 - incidence rates xiii–xiv
 - medico-legal considerations 181
 - mortality rates xv–xvi
- New Zealand Guidelines Group 183
- New Zealand Palliative Care: A Working Definition* 204–7
- New Zealanders 173–7
- noa 214
- nodular melanoma (NM) 7, 27, 46, 136, 203
- non-Caucasians 169–71
 - good practice points xxxvi, 171
- non-sentinel lymph nodes 81
 - histopathological reporting 50–1
- occult melanoma 141
 - evidence summary 141
 - recommendations xxxiv, 141
- occupational therapist 214
- ocular melanoma 143
 - evidence summary 143
 - recommendations xxxiv, 143
- oculoplastic surgeon 214
- odds ratio 214
- oesophagus, mucosal melanoma 135
- oncologist 214
- oncology 214
- oral melanoma 134
- Pacific peoples in New Zealand
 - good practice points xxxvi, 176
 - health perspectives 175–6
- palliative 214
- palliative care 113–16, 214
 - definition 113, 204–6
 - evidence summary 114, 116
 - generalist 114, 206–7
 - and multidisciplinary care 113
 - New Zealand definition 204–7
 - recommendations xxxii, 114, 115, 116
 - referral timing 114–15
 - referral to specialist 114–15
 - specialist 115–16, 207
- pathologists 214
- pathology reports
 - lymph node dissection 51–2
 - non-sentinel lymph nodes 50–1
 - sentinel lymph nodes 50–1
- pathology request forms 44
- patients
 - communication with 105–6
 - and complementary and alternative medicine (CAM) 164–5
 - detection of melanoma 27
 - high-risk
 - adjuvant systematic therapy 94
 - follow-up 123
 - good practice points xxi, 18
 - management of 18
 - risk factors 15–17
 - and psychosocial interventions 101–9
 - and specialist palliative care 115–16
- perineural 214
- periocular melanoma 143
- persistent melanoma 87
 - evidence summary 87
 - histological features 45
 - recommendations xxiii, 87
- physiotherapist 214
- PICO (populations, interventions, comparisons, outcomes) 215
- pigmented lesions 19
- plastic surgeon 215
- populations
 - Māori 173–4
 - non-Caucasians 149–50
 - Pacific peoples in New Zealand 175–6
- positron emission tomography (PET) 215
- precancerous 215
- pregnancy
 - after diagnosis 152

- evidence summary 151, 152
- and melanoma 152
- and naevi 151
- recommendations xxxv, 151, 152, 153
- transplacental transmission 145
- treatment during 152–3
- prevention 1–3
 - evidence summary 3
 - recommendations xxi, 3
- primary dermal melanoma 46, 203
- primary melanoma
 - evidence summary 56, 74
 - good practice points xxvii–xxviii, 75–6
 - investigations following diagnosis 55–6
 - versus metastatic melanoma 44
 - recommendations xxi, xxvi, 56, 75
 - treatment 73–6
- prognosis 157–8, 215
 - and age 158
 - body site of occurrence 157–8
 - and Breslow thickness 157–8
 - and Clark's level of invasion 157–8
 - and distant metastases 157–8
 - and gender 158
 - and lymphovascular invasion 157–8
 - and metastatic melanoma 157–8
 - and mitotic rate 158
 - and pregnancy 152
 - and psychosocial factors 106–8
 - and psychosocial interventions 108–9
 - and regression 157–8
 - and serum LDH 158
 - and TNM classification 157–8
 - and ulceration 157–8
- prognostic factors 157–8, 215
- prophylactic removal 18, 64
- protocol 215
- psycho-education 105
- psychosocial 215
- psychosocial factors
 - evidence summary 108
 - and prognosis 106–8
 - recommendations xxxi, 108
 - and survival 106–8
- psychosocial interventions
 - effect of 101–5
 - evidence summary 105, 109
 - and prognosis 108–9
 - recommendations xxxi, 105, 109
 - studies in other cancers 104
- psychosocial issues 101
- public consultation 187–8
- punch biopsy 35, 38
- radiologist 215
- radiology 215
- radiotherapy 95, 215
 - anorectal melanoma (ARM) 133
 - disseminated melanoma 95
 - lentigo maligna (LM) 69–70
 - and mucosal melanoma 133, 135
- randomised controlled trial (RCT) 127–8, 215
- recommendations
 - adjuvant systematic therapy xxx, 94
 - anorectal melanoma (ARM) xxxiii, 133
 - biopsy xxiii, 38
 - childhood melanoma xxxiv, 146, 147
 - classification and staging xxii
 - clinical diagnosis xxii, 31
 - clinical trials xxxii, 128
 - communication xxxi, 106
 - complementary and alternative medicine (CAM) xxxv, 165, 166, 167
 - congenital melanocytic naevi patients xxxv, 65
 - desmoplastic melanoma xxxiii, 129
 - disseminated melanoma xxxi, 97
 - follow-up xxxii, 122, 124
 - histopathological reporting xxiii–xxiv, 49–50, 51
 - lentigo maligna (LM) xxvi, 71
 - local metastasis 88, 89, 90
 - locoregional cutaneous melanoma xxiv, 58
 - locoregional recurrent melanoma xxix–xxx, 87, 88, 89, 90, 91
 - metastatic melanoma xxiv, 60
 - mucosal melanoma xxxiii–xxxiv, 133, 135
 - multidisciplinary care xxxii, 119
 - occult melanoma xxxiv, 141
 - ocular melanoma xxxiv, 143
 - palliative care xxxii, 114
 - persistent melanoma xxiii, 87
 - pregnancy xxxv, 151, 152, 153
 - prevention xxi, 3
 - primary melanoma xxi, xxvi, 56, 75
 - psychosocial factors xxxi, 108
 - psychosocial interventions xxxi, 105, 109

- regional lymph nodes xxiii, xxviii, 84, 90
- risk factors xxi–xxii, 18, 20
- sentinel lymph node biopsy (SLNB) xxiii, 82
- skin screening, whole-body xxi, 10
- staging 24
- summary of clinical practice recommendations xix–xxxvi
- vulval melanoma xxxiv, 137
- recurrence, local 44
- recurrent melanoma 39, 87–91, 137
- referral
 - to palliative care 114–15
 - to specialist 37, 79
- regional lymph nodes 79–84, 90–1
 - evidence summary 84, 90
 - good practice points xxix, 84
 - and metastatic melanoma 79
 - recommendations xxiii, xxviii, 84, 91
 - therapeutic dissection 82–4
- regression 42–3
 - and prognosis 157–8
- relative risks
 - sunbeds 1
- risk factors
 - age 15, 145, 153
 - congenital melanocytic naevi patients 63–4
 - ethnic origin 169–70
 - evidence summary 18, 20
 - family history 17
 - gender 15
 - genetic 19–20
 - melanocytic naevi 16
 - menstruation 153
 - and metastasis to lymph nodes 79
 - and pregnancy 151
 - previous melanoma 15
 - recommendations xxi–xxii, 18, 20
 - skin colour 16, 19
 - sun exposure 16
- Royal Australian College of General Practitioners
 - skin screening, whole-body 5
- satellitosis 88–90
- saucerisation 33
- scaring 45
- scintigraphy 215
- self-examination 27, 122
- sensitivity 215
- sentinel lymph node biopsy (SLNB) 79–82, 216
 - and children 146–7
 - evidence summary 82
 - recommendations xxiii, 82
- sentinel lymph nodes
 - histopathological reporting 50–1
- sequential digital imaging 30
- serum LDH
 - and prognosis 158
- skin colour
 - risk factors 16, 19
- skin pigmentation
 - and pregnancy 151
 - risk factors 16, 19
- skin screening, whole-body 5
 - accuracy of detection 6–7
 - cost-effectiveness 8
 - evidence summary 6, 7, 8, 9
 - melanoma thickness detected 7–8
 - proportion undergoing 5–6
 - recommendations xxi, 10
 - and reducing mortality 9
 - screening intervals 18
- solar elastosis 43
- solaria 1, 210
- specificity 216
- sphincter preservation 132, 134
- staging 23–6
 - cutaneous melanoma (CM) 26
 - evidence summary 24
 - recommendations 24
- submissions received 194–5
- subtypes 28
- subungual melanoma 28, 75
- summary of clinical practice recommendations xix–xxxvi
- sun exposure 1, 2, 16–17
- sun protection 2
- sun protection factor (SPF) 2
- sunscreen use 2–3
- superficial spreading melanoma *in situ* 46, 203
- superficial spreading melanoma (SSM) 7, 27, 46, 171, 203
- supportive care 216
- surgical oncologist 216
- surgical treatment

- and children 146–7
 - of desmoplastic melanoma 129
 - vulval melanoma 136–7
- survival xvi, 159
 - anorectal melanoma (ARM) 133
 - childhood melanoma 146–7
 - desmoplastic melanoma 43
 - and follow-up 124
 - mucosal melanoma 133, 135
 - and psychosocial factors 106–8
 - rates 159
 - trends xvi
- synonyms 46, 203
- synoptic reports 47–8
- systemic therapy 216
 - see also adjuvant systematic therapy

- tamoxifen 95
- tapu 216
- temozolomide 95
- terminology 46, 203
- therapeutic radiographer 216
- TNM classification 23–6
 - and prognosis 157–8
 - and survival rates 159
- topical therapy 216
- total body photography (TBP) 30
- transplacental transmission 145
- treatment
 - childhood melanoma 146–7
 - desmoplastic melanoma 129
 - lentigo maligna (LM) 69–71
 - during pregnancy 152–3
 - primary melanoma 73–6
- tumour 216
- tumour-infiltrating lymphocytes (TIL) 42

- ulceration 25, 42
 - and prognosis 157–8
- ultrasonography 122–3
- unclassified melanoma 46, 203
- UV radiation 1
- UVB radiation 1
- uveal melanoma 143

- vagina, mucosal melanoma 137
- vascular invasion 42, 45
- vitamin D 1–2
- vulval melanoma 136–7

- evidence summary 137
- management of 136–7
- recommendations xxxiv, 137

- whānau 216
- whānau ora 216
- wide local excision 38, 73–4, 79, 80, 132, 134, 137
- Working Party Membership 190–3
- World Health Organization, palliative care
 - definition 113, 204–5